LumibirdLTS:0FRI +2.74%81 Return-on-Tangible-Equity is 28.73% as of Dec. 2025, which is 61% above its 10-year median of 17.88. GuruFocus rates LTS:0FRI with a GF Score™ of 81/100 and a GF Value™ of €16.36 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Lumibird ranks better than 75.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lumibird's annualized net income for the quarter that ended in Dec. 2025 was €18.2 Mil. Lumibird's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €63.3 Mil. Therefore, Lumibird's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 28.73%.
The historical rank and industry rank for Lumibird's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0FRI'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.64 Med: 17.88 Max: 26.78
Current: 23.01
During the past 13 years, Lumibird's highest Return-on-Tangible-Equity was 26.78%. The lowest was 9.64%. And the median was 17.88%.
LTS:0FRI's Return-on-Tangible-Equity is ranked better than 75.77% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs LTS:0FRI: 23.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lumibird Return-on-Tangible-Equity Related Terms
Lumibird Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lumibird's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0FRI vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Lumibird's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lumibird's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 28.73% mean?
Lumibird (LTS:0FRI) has a Return-on-Tangible-Equity of 28.73% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lumibird and its competitors. This is 61% above median its historical median of 17.88. Over the past decade, Lumibird's Return-on-Tangible-Equity has ranged from 9.64 to 26.78. According to the industry distribution chart, Lumibird ranks #47 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 24.2%.
Is Lumibird's Return-on-Tangible-Equity too high?
Lumibird's current Return-on-Tangible-Equity of 28.73% is 61% above median its 10-year median of 17.88. Over the past 10 years, this metric has ranged from a low of 9.64 to a high of 26.78. Based on the distribution chart, Lumibird ranks #47 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lumibird has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #47 out of 194 companies for Return-on-Tangible-Equity. This places Lumibird in the top 24% of its industry — outperforming the majority of peers. Historically, Lumibird's own Return-on-Tangible-Equity has ranged from 9.64 to 26.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lumibird and its competitors. Lumibird's current Return-on-Tangible-Equity is 28.73%, which is 61% above median its own 10-year median of 17.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (LTS:0FRI) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.36, compared to a current price of €26.25 — trading 60.5% above its estimated fair value. The current Return-on-Tangible-Equity is 28.73%, which is 61% above median its 10-year median of 17.88. Lumibird's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lumibird (LTS:0FRI), the current Return-on-Tangible-Equity is 28.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (LTS:0FRI) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €26.25 is trading 60.5% above its estimated GF Value™ of €16.36.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for LTS:0FRI:
Return-on-Tangible-Equity: 28.73% (61% above median its 10-year median of 17.88)
GF Value™: €16.36 vs. price of €26.25 (60.5% above fair value)
No single metric tells the full story. See the LTS:0FRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
81GF Score
Get the complete analysis for LTS:0FRI
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0FRI has been successfully added to your 
